“The grant we received from the European Innovation Council is a strong validation of NeuroRestore ACD856, which has a unique pharmacological mechanism that enables multiple indications, both neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, but also, for example, depression,” said Martin Jönsson, CEO of AlzeCure Pharma. ”That ACD856 has the potential to both improve learning and memory capacity, as well as being disease-modifying and improving brain health is unique and significant”.
Read more here: AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer’s disease
Link to the EIC Accelerator announcement